Volume 22, Number 9—September 2016
CME ACTIVITY - Research
Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase–Producing Escherichia coli Infections in Patients with Pyelonephritis, United States1
Table 5
Factor | ESBL-producing E. coli rate |
Relative risk (95% CI) | |
---|---|---|---|
Factor present, no./total (%) | Factor absent, no./total (%) | ||
Age >65 y | 4/22 (18.2) | 25/431 (5.8) | 3.1 (0.96–8.1) |
Complicated infection |
22/181 (12.2) |
7/272 (2.6) |
4.7 (2.0–12.0) |
Prior antimicrobial drugs | |||
Within past 60 d | 16/94 (17.0) | 13/359 (3.6) | 4.7 (2.2–10.0) |
Within past 2 d |
4/27 (14.8) |
25/426 (5.9) |
2.5 (0.8–6.7) |
IV antimicrobial drugs taken within past 30 d | 4/26 (15.4) | 25/425 (5.9) | 2.6 (0.8–6.9) |
LTC within past 90 d | 1/3 (33.3) | 28/450 (6.2) | 5.4 (0.3–14.9) |
Hospital admittance within past 90 d | 5/42 (11.9) | 24/411 (5.8) | 2.0 (0.7–5.2) |
Travel outside United States within past 90 d |
4/17 (23.5)† |
25/436 (5.7) |
4.1 (1.3–10.1) |
UTI caused by fluoroquinolone-resistant E. coli | |||
Within past year | 5/9 (55.6) | 24/444 (5.4) | 10.3 (3.8–17.5) |
Within past 90 d |
5/8 (62.5) |
24/445 (5.4) |
11.6 (4.4–18.3) |
UTI caused by ceftriaxone-resistant E. coli | |||
Within past year | 5/6 (83.3) | 24/447 (5.4) | 15.5 (6.2 −19.2) |
Within past 90 d |
5/5 (100.0) |
24/448 (5.4) |
18.7 (8.0–18.7) |
Fluoroquinolone resistance | 24/53 (45.3) | 5/400 (1.3) | 36.2 (14.2–104.7) |
*Denominators differ because factors have a different distribution among the patient population. ESBL, extended spectrum β-lactamase; IV, intravenous; LTC, residence in a long-term care facility; UTI, urinary tract infection.
†Of these 4 patients who traveled to other regions, 3 traveled to Mexico or Central America and 1 traveled to Asia.
1Preliminary results of this research were presented at the 2014 IDWeek Meeting, Philadelphia, PA, USA, October 8–12, 2014.
Page created: August 11, 2016
Page updated: August 11, 2016
Page reviewed: August 11, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.